This study is testing a new treatment called IMNN-001 (an IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) for newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers want to see if adding IMNN-001 to standard chemotherapy (Paclitaxel and Carboplatin) and Bevacizumab (BEV) is safe and effective. You may be eligible if you are a woman aged 18 or older with high-grade serous adenocarcinoma. The main goal is to measure how much cancer remains (Minimal Residual Disease) after 8 months. The study is currently recruiting about 30 participants, but its exact status is unclear.

Study design

This is a Phase 1/2, randomized, open-label study involving multiple centers. About 30 participants will be randomly assigned to receive either the standard chemotherapy plus Bevacizumab, or the standard treatment plus IMNN-001.

What's involved

You will receive chemotherapy and Bevacizumab every three weeks for 7-9 cycles, with IMNN-001 added weekly in the experimental arm. This includes at least 4 cycles before surgery and 3 cycles after surgery.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, Minimal Residual Disease, is measured at 8 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.